IDARUBICIN News

IDARUBICIN currently has 8 news articles, with 16 predicted indications.

This page combines the AI-predicted indications for IDARUBICIN with the latest health news. Indications highlighted in orange have recent news coverage.

Drug Information

Evidence level: L5
Predicted indications (16):
- acute myeloid leukemia with t(8;16)(p11;p13) translocation (99.0%)
- acute myeloblastic leukemia without maturation (99.0%)
- inherited acute myeloid leukemia (99.0%)
- acute myeloid leukemia with t(6;9)(p23;q34) (99.0%)
- acute myeloid leukemia with t(9;11)(p22;q23) (99.0%)
- therapy related acute myeloid leukemia and myelodysplastic syndrome (99.0%)
- acute promyelocytic leukemia (99.0%)
- acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) (99.0%)
- acute myeloid leukemia with NPM1 somatic mutations (99.0%)
- acute myeloid leukemia with minimal differentiation (99.0%)
- acute myeloid leukemia with CEBPA somatic mutations (99.0%)
- myeloid leukemia (99.0%)
- acute myeloid leukemia with t(8;21)(q22;q22) translocation (99.0%)
- acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor (99.0%)
- acute myeloblastic leukemia with maturation (99.0%)
- unclassified acute myeloid leukemia (99.0%)